Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.


Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Forschungszentrum Juelich, Juelich, Germany; Center of Integrated Oncology (CIO), University of Cologne, Cologne, Germany. Electronic address: [Email]


We here report findings on magnetic resonance imaging from a 60-year-old patient with an epithelioid glioblastoma of the corpus callosum treated with radiotherapy in combination with concomitant and adjuvant temozolomide. Neuropathology revealed a highly aggressive molecular subtype of the epithelioid glioblastoma without an isocitrate dehydrogenase and B-Raf proto-oncogene mutation or a O6-methylguanine-DNA-methyltransferase promoter hypermethylation. This subtype is typically associated with an unfavorable clinical course and poor overall survival. Unexpectedly, the first follow-up magnetic resonance imaging 10 weeks after chemoradiation completion revealed an early and almost complete treatment response.


Brain tumors,Chemoradiation,Glioma,Neuroimaging,Temozolomide,